Physiologic aspects of aging: Impact on cancer management and decision making, part I

Cancer Journal

Volumn 11, Issue 6, 2005, Pages 449-460

  Sawhney, Rishi ^a,b   Sehl, Mary ^a,b   Naeim, Arash ^a,b  

^a University of California ^*

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer therapy; Frailty; Functional reserve; Geriatric oncology; Physiological changes; Treatment toxicity

Indexed keywords

ALEMTUZUMAB; AMIFOSTINE; ANTHRACYCLINE; BEVACIZUMAB; CISPLATIN; IMATINIB; RITUXIMAB; TRASTUZUMAB;

AEROBIC CAPACITY; AGING; CANCER; CANCER RADIOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; ELDERLY CARE; ESOPHAGITIS; GASTROINTESTINAL TRACT FUNCTION; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART RATE AND RHYTHM; HEART VENTRICLE FUNCTION; HEPATOBILIARY SYSTEM; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FUNCTION; MEDICAL DECISION MAKING; NEPHROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

AGED; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR PHYSIOLOGY; DECISION MAKING; GASTROINTESTINAL TRACT; HUMANS; KIDNEY; NEOPLASMS; RESPIRATORY PHYSIOLOGY;

EID: 30744434127     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200511000-00004     Document Type: Review

References (136)

1. Taffet G. Physiology of aging. In: Cassell CK, Leipzig RM, Cohen HJ, et al, eds. Geriatric Medicince: An Evidence Based Approach. 4th ed. New York: Springer;2003:27-35.
2. Ries L, Eisner M, Kosary C et al. SEER Cancer Statistics Review, 1975-2002. www.seer.cancer.gov/csr/1975_2002., 2004
3. Yancik R, Ries LA. Aging and cancer in America. Demo graphic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-23.
4. Solicit S, Lakatta E. Normal aging changes in the cardiovas cular system. Cardiology Elderly 1993;1:349-358.
5. Mittelmark MB, Psaty BM, Rautaharju PM et al., Prevalence of cardiovascular diseases among older adults. The Cardiovascular Health Study. Am J Epidemiol 1993;137:311-317.
6. Lakatta EG. Cardiovascular reserve capacity in healthy older humans. Aging (Milano) 1994;6:213-223.
7. Bharati S, Lev M. Pathologic changes of the conduction system with aging. Cardiol Elderly 1994;2:152-160.
8. Hano O, Bogdanov KY, Sakai M et al. Reduced threshold for myocardial cell calcium intolerance in the rat heart with aging. Am J Physiol 1995;269[suppl 5, pt 2]:H1607-H1612.
9. Schulman S, Lakatta EG, Fleg JL et al. Age-related decline in left ventricular filling at rest and exercise. Am J Physiol 1992;263[suppl 6, pt 2]:H1932-H1938.
10. Swinne CJ, Shapiro EP, Lima SD et al. Age-associated changes in left ventricular diastolic performance during isometric exercise in normal subjects. Am J Cardiol 1992;69:823-826.
11. Lernfelt B, Wikstrand J, Svanborg A et al. Aging and left ventricular function in elderly healthy people. Am J Cardiol 1991;68:547-549.
12. Fleg JL, O'Connor F, Gerstenblith G et al. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. J Appl Physiol 1995;78;890-900.
13. Martinez-Selles M, Garcia Robles JA, Prieto L et al. Heart failure in the elderly: age-related differences in clinical profile and mortality. Int J Cardiol 2005;102:55-60.
14. Fleg JL, Lakatta EG. Role of muscle loss in the age-associated reduction in VO2 max. J Appl Physiol 1988;65:1147-1151.
15. Kates AM, Herrero P, Dence C et al. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol 2003;41:293-299.
16. Lindroos M, Kupari M, Heikkila J et al. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993;21: 1220-1225.
17. Guyton JR, Lindsay KL, Dao DT. Comparison of aortic intima and inner media in young adult versus aging rats. Stereology in a polarized system. Am J Pathol 1983;111:234-246.
18. Nagai Y, Metter EJ, Earley CJ et al. Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exercise-induced myocardial ischemia. Circulation 1998;98: 1504-1509.
19. Schutzer WE, Mader SL. Age-related changes in vascular adrenergic signaling: clinical and mechanistic implications. Ageing Res Rev 2003;2:169-190.
20. van der Loo B, Koppensteiner R, Luscher TF [How do blood vessels age? Mechanisms and clinical implications]. Vasa 2004;33:3-11.
21. Woodman CR, Price EM, Laughlin MH. Selected contribution: Aging impairs nitric oxide and prostacyclin mediation of endothelium-dependent dilation in soleus feed arteries. J Appl Physiol 2003;95:2164-2170.
22. Yeh ET, Tong AT, Lenihan DJ et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-3131.
23. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
24. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-2879.
25. Brockstein BE, Smiley C, Al-Sadir J et al. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 2000;25:885-894.
26. Nieto Y, Cagnoni PJ, Beaman SI et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-1) for breast cancer. Biol Blood Marrow Transplant 2000;6:198-203.
27. Lenihan DJ, Alencar AJ, Yang D et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004;104:655-658.
28. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(suppl 16): 117-124.
29. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215-1221.
30. Legha SS, Benjamin RS, Mackay B et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-139.
31. Gabizon AA, Lyass O, Berry GJ et al. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 2004;22:663-669.
32. van Dalen EC, Caron HN, Dickinson HO et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005:CD003917.
33. Schuchter LM, Hensley ML, Meropol NJ et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20;2895-2903.
34. Ewer MS, Ali MK, Gibbs HR et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol 1994; 33:645-649.
35. Marchandise B, Schroeder E, Bosly A et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92-98.
36. Weesner KM, Bledsoe M, Chauvenet A et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 1991;68:435-438.
37. Nousiainen T, Jantunen E, Vanninen E et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999;62: 135-141.
38. Tong AT, Lenihan D, Divakaran V et al. B-type natriuretic peptide is a biochemical predictor of myocardial contractile reserve during dobutamine stress echocardiogram. J Am Coll Cardiol 2004;43:173A.
39. Navazesh M, Milligan RA, Kipnis V et al. Comparison of whole saliva flow rates and mucin concentrations in healthy Caucasian young and aged adults. J Dent Res 1992;71:1275-1278.
40. Nagaya M, Sumi Y. Reaction time in the submental muscles of normal older people. J Am Geriatr Soc 2002;50:975-976.
41. Shaker R, Ren J, Podvrsan B et al. Effect of aging and bolus variables on pharyngeal and upper esophageal sphincter motor function. Am J Physiol 1993;264[suppl 3, pt 1]:G427-G432.
42. Hollis JB, Castell DO. Esophageal function in elderly man. A new look at "presbyesophagus". Ann Intern Med 1974;80: 371-374.
43. Taha AS, Angerson W, Nakshabendi I et al. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs-influence of age, smoking, ulceration and Helicobacter pylori. Aliment Pharmacol Ther 1993; 7:41-45.
44. Lee M. Age-related changes in gastric blood flow in rats. Gerontology 1996;42:289-293.
45. Katelaris PH, Seow F, Lin BP et al. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. Gut 1993;34: 1032-1037.
46. Feldman M, Cryer B, McArthur KE et al. Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study. Gastroenterology 1996;110:1043-1052.
47. Cryer B, Lee E, Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: roles of smoking and aging. Ann Intern Med 1992;116:636-640.
48. Cryer B, Redfen JS, Goldschmiedt M et al. Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterology 1992;102[suppl 4, pt 1]:1118-1123.
49. Vogiagis D, Glare EM, Misajon A et al. Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: effects of aging and ulcers. Am J Physiol Gastrointest Liver Physiol 2000;278:G820-G827.
50. Goldschmiedt M, Barrett CC, Schwarz BE et al. Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women. Gastroenterology 1991;101:977-990.
51. Massarrat S, Schumann KM, Schwarz ER. Variation of total pepsin activity in sera with age and under different stimulations of gastric acid secretion. Clin Biochem 1989;22:99-101.
52. Rashid MU, Bateman DN. Effect of intravenous atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers. Br J Clin Pharmacol 1990;30:25-34.
53. Wegener M, Borsch G, Schaffstein J et al. Effect of ageing on the gastro-intestinal transit of a lactulose-supplemented mixed solid-liquid meal in humans. Digestion 1988;39: 40-46.
54. Kao CH, Lai TL, Wang SJ et al. Influence of age on gastric emptying in healthy Chinese. Clin Nucl Med 1994;19: 401-404.
55. Clarkston WK, Pantano MM, Morley JE et al. Evidence for the anorexia of aging: gastrointestinal transit and hunger in healthy elderly vs. young adults. Am J Physiol 1997; 272[suppl 1, pt 2]:R243-R248.
56. Riezzo G, Pezzolla F, Giorgio I. Effects of age and obesity on fasting gastric electrical activity in man: a cutaneous electro-gastrographic study. Digestion 1991;50:176-181.
57. McLean AJ, Le Couleur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56:163-184.
58. Newton JL. Changes in upper gastrointestinal physiology with age. Mech Ageing Dev 2004;125:867-870.
59. Newton JL, Allen A, Westley BR et al. The human trefoil peptide, TFF1, is present in different molecular forms that are intimately associated with mucus in normal stomach. Gut 2000;46:312-320.
60. Hackelsberger A, Platzer V, Nilius M et al. Age and Helicobacter pylori decrease gastric mucosal surface hydrophobicity independently. Gut 1998;43:465-469.
61. Corfield AP, Wagner SA, Safe A et al. Sialic acids in human gastric aspirates: detection of 9-O-lactyl- and 9-O-acetyl-N-acetylneuraminic acids and a decrease in total sialic acid concentration with age. Clin Sci (Lond) 1993;84:573-579.
62. Feldman M, Cryer B, Lee E. Effects of Helicobacter pylori gastritis on gastric secretion in healthy human beings. Am J Physiol 1998;274[suppl6, pt 1]:G1011-G1017.
63. Guslandi M, Pellegrini A, Sorghi M. Gastric mucosal defences in the elderly. Gerontology 1999;45:206-208.
64. Kim SW, Parekh D, Townsend CM Jr et al. Effects of aging on duodenal bicarbonate secretion. Ann Surg 1990;212:332-337; discussion 337-338.
65. Husebye E, Engedal K. The patterns of motility are maintained in the human small intestine throughout the process of aging. Scand J Gastroenterol 1992;27:397-404.
66. Nobles LB, Marcuard SP, Farrior ES et al. No effect of fiber and age on oral cecum transit time of liquid formula diets in women. J Am Diet Assoc 1991;91:600-602.
67. Saffrey MJ. Ageing of the enteric nervous system. Mech Ageing Dev 2004;125:899-906.
68. Johnson SL, Mayersohn M, Conrad KA. Gastrointestinal ab Sorption as a function of age: xylose absorption in health adults. Clin Pharmacol Ther 1985;38:331-335.
69. Mayersohn M. The "Xylose test" to assess gastrointestinal ab sorption in the elderly: a pharmacokinetic evaluation of the literature. J Gerontol 1982;37:300-305.
70. Saltzman JR, Russell RM. The aging gut. Nutritional issues Gastroenterol Clin North Am 1998;27:309-324.
71. Laugier R, Bernard JP, Berthezene P et al. Changes in pancreatic exocrine secretion with age: pancreatic exocrine secretion does decrease in the elderly. Digestion 1991;50:202-211.
72. Fabbri A, Marchesini G, Bianchi G et al. Kinetics of hepati amino-nitrogen conversion in ageing man. Liver 1994;14: 288-294.
73. Wynne HA, Cope LH, Mutch E et al. The effect of age upon liver volume and apparent liver blood flow in healthy man Hepatology 1989;9:297-301.
74. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004;2:274-302.
75. Marchesini G, Bua V, Brunori A et al. Galactose elimination capacity and liver volume in aging man. Hepatology 1988;8: 1079-1083.
76. Sotaniemi EA, Arranto AJ, Pelkonen O et al. Age and cy tochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions Clin Pharmacol Ther 1997;61:331-339.
77. Marchesini G, Bianchi GP, Fabbri A et al. Synthesis of urea after a protein-rich meal in normal man in relation to ageing Age Ageing 1990;19:4-10.
78. Gentile S, Persico M, Orlando C et al. Age-associated decline of hepatic handling of cholephilic anions in humans is re verted by S-adenosylmethionine (SAMe). Scand J Clin Lab Invest 1990;50:565-571.
79. Wedmann B, Schmidt G, Wegener M et al. Effects of age and gender on fat-induced gallbladder contraction and gastric emptying of a caloric liquid meal: a sonographic study. Am Gastroenterol 1991;86:1765-1770.
80. Salemans JM, Nagengast FM, Tangerman A et al. Effect of age ing on postprandial conjugated and unconjugated serum bile acid levels in healthy subjects. Eur J Clin Invest 1993;23:192-198.
81. Nagengast FM, van der Werf SD, Lamers HL et al. Influence of age, intestinal transit time, and dietary composition on fecal bile acid profiles in healthy subjects. Dig Dis Sci 1988; 33:673-678.
82. Balducci L. Geriatric oncology. Crit Rev Oncol Hematol 2003;46:211-220.
83. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000;5:224-237.
84. Saadeh CE. Chemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment. Pharmacotherapy 2005;25:540-554.
85. Antonadou D, Coliarakis N, Synodinou M et al. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 2001;51:915-922.
86. Wilcock A, Thomas J, Frisby J et al. Potential for drug inter actions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit. Br J Clin Pharmacol. 2005;60:326-329.
87. Turner JM, MeadJ, Wohl ME. Elasticity of human lungs in re lation to age. J Appl Physiol 1968;25:664-671.
88. Ware JH, Dockery DW, Louis TA et al. Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiol 1990;132:685-700.
89. Mahler DA, Rosiello RA, Loke J. The aging lung. Clin Geriatr Med 1986;2:215-225.
90. Rossi A, Ganassini A, Tantucci C et al. Aging and the respiratory system. Aging (Milano) 1996;8:143-161.
91. Teramoto S, Suzuki M, Matuse T et al. [Influence of kyphosis on the age-related decline in pulmonary function]. Nippon Ronen Igakkai Zasshi 1998;35:23-27.
92. Gyetko MR, Toews GB. Immunology of the aging lung. Clin Chest Med 1993;14:379-391.
93. Girinsky T, Cosset JM. [Pulmonary and cardiac late effects of ionizing radiations alone or combined with chemotherapy]. Cancer Radiother 1997;1:735-743.
94. Connolly MJ, CrowleyJJ, Charan NB et al. Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax 1992;47:410-413.
95. Ashley F, Kannel WB, Sorlie PD et al. Pulmonary function: relation to aging, cigarette habit, and mortality. Ann Intern Med 1975;82:739-745.
96. Griffith KA, Sherrill DL, Siegel EM et al. Predictors of loss of lung function in the elderly: the Cardiovascular Health Study. Am J Respir Crit Care Med 2001;163:61-68.
97. Niederstadt C, Steinhoff J. [The kidneys in aging]. Z Gerontol Geriatr 1997;30:200-207.
98. Akiyama M, Sakaguchi H. [Morphological study of renal changes with age: the possibility of kidney donations by the elderly]. NipponJinzo Gakkai Shi 1990;32:751-756.
99. Beck LH. Changes in renal function with aging. Clin Geriatr Med 1998;14:199-209.
100. Lubran MM. Renal function in the elderly. Ann Clin Lab Sci 1995;25:122-133.
101. Griffiths GJ, Robinson KB, Cartwright GO et al. Loss of renal tissue in the elderly. Br J Radiol 1976;49:111-117.
102. Melk A, Halloran PF. Cell senescence and its implications for nephrology J Am Soc Nephrol 2001;12:385-393.
103. Fuiano G, Sund S, Mazza G et al. Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects. Kidney Int 2001;59:1052-1058.
104. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999;45:243-253.
105. Adachi T, Kawamura M, Owada M et al. Effect of age on renal functional and orthostatic vascular response in healthy men. Clin Exp Pharmacol Physiol 2001;28:877-880.
106. Thomas SE, Anderson S, Gordon KL et al. Tubulointerstitial disease in aging: evidence for underlying peritubular capillary damage, a potential role for renal ischemia. J Am Soc Nephrol 1998;9:231-242.
107. Neugarten J, Gallo G, Silbiger S et al. Glomerulosclerosis in aging humans is not influenced by gender. Am J Kidney Dis 227-234.
108. Kaplan C, Pasternack B, Shah H et al. Age-related incidence of sclerotic glomeruli in human kidneys. Am J Pathol 1975;80: 227-234.
109. Kappel B, Olsen S. Cortical interstitial tissue and sclerosed glomeruli in the normal human kidney, related to age and sex. A quantitative study. Virchows Arch A Pathol Anat Histol 1980;387:271-277.
110. Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987;31: 1153-1159.
111. Langeveld JP, Veerkamp JH, Duyf CM et al. Chemical characterization of glomerular and tubular basement membranes of men of different age. Kidney Int 1981;20:104-114.
112. Martin GM, Ogburn CE, Colgin LM et al. Somatic mutations are frequent and increase with age in human kidney epithelial cells. Hum Mol Genet 1996;5:215-221.
113. Baylis C, Schmidt R. The aging glomerulus. Semin Nephrol 1996;16:265-276.
114. Li YM, Steffes M, Donnelly T et al. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 1996;93: 3902-3907.
115. Melk A, Ramassar V, Helms LM et al. Telomere shortening in kidneys with age. J Am Soc Nephrol 2000;11:444-453.
116. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950;29:496-507.
117. DeSanto NG, Anastasio P, Coppola S et al. Age-related changes in renal reserve and renal tubular function in healthy humans. Child Nephrol Urol 1991;11:33-40.
118. Rowe JW, Andres R, Tobin JD et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976;31:155-163.
119. Danziger RS, Tobin JD, Becker LC et al. The age-associated decline in glomerular filtration in healthy normotensive volunteers. Lack of relationship to cardiovascular performance. J Am Geriatr Soc 1990;38:1127-1132.
120. Sokoll LJ, Russell RM, Sadowski JA et al. Establishment of creatinine clearance reference values for older women. Clin Chem 1994;40:2276-2281.
121. Marcus R, Madvig P, Young G. Age-related changes in parathyroid hormone and parathyroid hormone action in normal humans J Clin Endocrinol Metab 1984;58:223-230.
122. Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004;38:73-77.
123. Sanaka M, Takano K, Shimakura K et al. Serum albumin for estimating creatinine clearance in the elderly with muscle atrophy. Nephron 1996;73:137-144.
124. Schuck O, Nadvornikova H, Teplan V. Acidification capacity of the kidneys and aging. Physiol Bohemoslov 1989;38: 117-125.
125. Corman B, Barrault MB, Klingler C et al. Renin gene expression in the aging kidney: effect of sodium restriction. Mech Ageing Dev 1995;84:1-13.
126. Luft FC, Fineberg NS, Weinberger MH. The influence of age on renal function and renin and aldosterone responses to sodium-volume expansion and contraction in normotensive and mildly hypertensive humans. Am J Hypertens 1992;5: 520-528.
127. Os I, Kjeldsen SE, Westheim A et al. Aging and urinary vasopressin excretion in healthy men. Scand J Urol Nephrol 1987; 21:235-239.
128. Helderman JH, Vestal RE, Rowe JW et al. The response of arginine vasopressin to intravenous ethanol and hypertonic saline in man: the impact of aging. J Gerontol 1978;33:39-47.
129. Corman B, Roinel N, Geelen G. Plasma vasopressin and cortical nephron function in aging rats. Mech Ageing Dev 1992; 62:263-277.
130. Chapuy MC, Durr F, Chapuy P. Age-related changes in parathyroid hormone and 25 hydroxycholecalciferol levels. J Gerontol 1983;38:19-22.
131. Kotowicz MA, Melton LF 3rd, Cedel SL et al. Effect of age on variables relating to calcium and phosphorus metabolism in women. J Bone Miner Res 1990;5:345-352.
132. Beaufrere B, Morio B. Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 2000; 54[suppl3]:S48-S53.
133. Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging 1998;13:357-379.
134. Fliser D, Bischoff I, Hanses A et al. Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol 1999;55:205-211.
135. Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages II and IV ovarian cancer. J Clin Oncol 1992;10:706-717.
136. Schiller JH, Berry W, Storer B et al. Phase II trial of amifostine cisplatin and vinblastine for metastatic non-small cell lung cancer [Abstract 1084]. Proc Am Soc Clin Oncol 1995; 14:356.